[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"testicular-germ-cell-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:testicular-germ-cell-tumor":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,87,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100054003","minimally-invasive-icg-guided-retroperitoneal-sentinel-lymph-node-dissection-in-the-primary-staging-of-testicular-cancer-versus-standard-of-care-100054003",false,"NCT07699640","Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care","RAISN 2: Prospective Randomized Trial of Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care","RAISN 2","Inclusion Criteria:\n\n* Male participants aged 18 years or older.\n* Clinically suspected testicular germ cell tumor based on physical examination and scrotal ultrasonography, with or without elevated serum tumor markers (AFP and\u002For β-hCG).\n* No radiological evidence of metastatic disease on preoperative contrast-enhanced computed tomography (CT) of the chest and abdomen (clinical stage I).\n* Eligible for radical inguinal orchiectomy.\n* Able to understand the study procedures and provide written informed consent.\n* Willing and able to comply with the study protocol and follow-up schedule.\n\nExclusion Criteria:\n\n* Previous scrotal or retroperitoneal surgery unrelated to germ cell tumor treatment, except surgery for cryptorchidism during childhood.\n* Previous malignancy requiring abdominal surgery, chemotherapy, or radiotherapy that could interfere with study participation.\n\nPrevious radiotherapy involving the retroperitoneum.\n\n* Known hypersensitivity to indocyanine green (ICG), iodine, or sodium iodide.\n* Severe medical condition that precludes surgery or study participation.\n* Psychiatric disorder or other condition preventing compliance with study procedures.\n* Inability to understand the German language sufficiently to provide informed consent and complete study assessments.\n* Individuals under legal guardianship or otherwise unable to provide legally valid informed consent.","MALE","18 Years",{"count":20,"type":21},171,"ESTIMATED","INTERVENTIONAL",[24],"NA","Testicular cancer is highly curable, but approximately 20-30% of patients with clinical stage I disease harbor occult retroperitoneal lymph node metastases that are not detected by conventional imaging. Current risk-adapted management may lead to overtreatment in some patients while failing to identify others who are at increased risk of relapse.\n\nThe RAISN 2 study evaluates whether minimally invasive indocyanine green (ICG)-guided retroperitoneal sentinel lymph node dissection can improve primary staging and risk stratification in patients with clinical stage I testicular cancer. Participants will be randomized in a 5:1 ratio to undergo either orchiectomy combined with ICG-guided sentinel lymph node dissection or standard orchiectomy followed by guideline-based surveillance.\n\nAll participants will undergo structured follow-up according to current clinical guidelines. The primary objective is to estimate the 2-year relapse-free survival of patients undergoing the sentinel lymph node approach. Secondary objectives include assessment of overall survival, relapse patterns, perioperative morbidity, quality of life, psychological outcomes, and the feasibility and safety of the procedure.\n\nThis multicenter study aims to determine whether sentinel lymph node-guided staging provides more accurate risk stratification while avoiding unnecessary treatment and maintaining oncological safety.",[27,28],"Testicular Cancer","Testicular Germ Cell Tumor",[27,28,30,31,32,33,34,35,36,37,38],"Stage I Testicular Cancer","Sentinel Lymph Node Biopsy","Sentinel Lymph Node Mapping","Indocyanine Green","ICG","Retroperitoneal Lymph Nodes","Minimally Invasive Surgery","Robot-Assisted Surgery","Active Surveillance","NOT_YET_RECRUITING","2026-07-08",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":21},"2027-01",{"date":47,"type":21},"2031-01",{"name":49,"class":50},"Heinrich-Heine University, Duesseldorf","OTHER",10,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100537335","phase-1-phase-1-safety-and-tolerability-study-of-xmab541-in-advanced-solid-tumors-100537335","NCT06276491","Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors","A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years. For US only: subjects with GCTs, age ≥15 years\n* CLDN6+ tumor\n* Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcinoma of the endometrium (endometrial cancer, uterine cancer, or carcinoma of the uterine corpus), GCT resistant to previous treatment\n* Adequate Eastern Cooperative Oncology Group performance status\n* Life expectancy ≥ 3 months\n* Adequate liver, kidney, and bone marrow function\n\nKey Exclusion Criteria:\n\n* Patients with treated brain metastases may participate, provided they are radiologically stable.\n* Active known or suspected autoimmune disease\n* Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug\n* Clinically significant cardiovascular, pulmonary or gastrointestinal disease\n* Active hepatitis B or hepatitis C","ALL","15 Years",{"count":62,"type":21},282,[64],"PHASE1","The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.",[67,68,69,28,70],"Ovarian Cancer","Endometrial Cancer","Germ Cell Tumor","Ovarian Germ Cell Tumor",[72,67,73,27,69,68,74],"Phase 1","CLDN6","T-cell Engager","RECRUITING","2026-06-09",{"date":78,"type":43},"2026-06-11",{"date":80,"type":43},"2024-04-04",{"date":82,"type":21},"2028-12",{"name":84,"class":85},"Xencor, Inc.","INDUSTRY",18,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100627780","a-prospective-study-to-evaluate-mirna371-and-outcomes-in-patients-with-newly-diagnosed-germ-cell-tumors-100627780","NCT07453082","A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors","A Prospective Observational Cohort Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumor","BRIDGE","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age.\n* Patients must have a new diagnosis of a germ cell tumor confirmed pathologically or serologically (diagnostic elevation of HCG\u002FAFP). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible.\n* If surgery is planned, male patients with Clinical Stage I testicular cancer must have orchiectomy completed within 42 days prior to registration.\n* Patients must have risk of relapse assessment determined by the local investigator prior to registration.\n* Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected.\n* Patients must have beta-human chorionic gonadotropin (beta-HCG), alpha- fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration.\n* Patients must agree to provide informed consent and required blood specimens for the duration of the study.\n\nExclusion Criteria:\n\n* Patients with high risk of relapse or metastatic disease.\n* Patients with tumour assessments beyond the time frame required by the protocol.\n* Patients not complaint with the protocol schedule.",{"count":96,"type":21},100,"OBSERVATIONAL","This is a observational study aimed at evaluating miRNA 371a-3p (miRNA 371) as a specific marker for presence or absence of clinically detectable viable germ cell malignancy.",[28],"2026-03-03",{"date":102,"type":43},"2026-03-05",{"date":104,"type":43},"2021-07-01",{"date":106,"type":21},"2026-12-31",{"name":108,"class":50},"Fondazione del Piemonte per l'Oncologia",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":109},"100490808","follow-up-after-surgery-for-testicular-cancer-100490808","NCT05670938","Follow-up After Surgery for Testicular Cancer","Follow-up After Surgery for Testicular Cancer: the Prospective, Single Centre FUTURE-testis Implementation Study","FUTURE-testis","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed testicular cancer without distant metastasis and treated with curative intent less than 3 months ago:\n\n  1\\. Non-seminomatous germ cell tumours, stage I low risk:\n* No lymphadenopathy or metastases on the postoperative scan.\n* Three consecutive blood drawings with normal tumour markers.\n* Patients undergoing lymph node dissection as a second curative operation after an orchiectomy, can also be included in case that the postoperative scan shows no residual disease or metastases.\n\n  2\\. Non-seminomatous germ cell tumours, stage I high risk:\n* After completion of one cycle of Bleomycin, etoposide and platinum (BEP).\n* Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.\n* No lymphadenopathy or metastases on the CT scan after completion of chemotherapy.\n\n  3\\. Seminomatous or non-seminomatous germ cell tumours (after chemotherapy) with complete remission.\n* Biochemical remission at completion of chemotherapy, meaning three consecutive blood drawings with normal tumour markers.\n* No lymphadenopathy or metastases on the CT scan after completion of chemotherapy.\n* Scheduled or currently undergoing postoperative surveillance according to national and European guidelines.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with aberrant levels of LDH preoperatively (LDH \\>248 U\u002FL).\n* Patients enrolled in other studies that require strict adherence to any specific follow-up practice with regular imaging - yearly or more frequent - of the abdomen and\u002For thorax\n* Patients with comorbidity or other malignancy that requires imaging of the abdomen and\u002For thorax every year or more frequent\n* Inability to complete the questionnaires due to illiteracy and\u002For insufficient proficiency of the Dutch language",{"count":119,"type":21},145,"The currently developed implementation study aims to evaluate if a patient-led home-based follow-up approach is successful, improves quality of life, reduces anxiety and lessens fear of cancer recurrence during the years after treatment of certain types of testicular cancer.",[27,28,122],"Quality of Life",[124],"Follow-up","2023-02-22",{"date":127,"type":43},"2023-02-23",{"date":129,"type":43},"2022-11-30",{"date":131,"type":21},"2030-12",{"name":133,"class":50},"Erasmus Medical Center"]